232 related articles for article (PubMed ID: 37182534)
1. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).
Kaye KS; Shorr AF; Wunderink RG; Du B; Poirier GE; Rana K; Miller A; Lewis D; O'Donnell J; Chen L; Reinhart H; Srinivasan S; Isaacs R; Altarac D
Lancet Infect Dis; 2023 Sep; 23(9):1072-1084. PubMed ID: 37182534
[TBL] [Abstract][Full Text] [Related]
2. Characterization of
Miller AA; Moussa SH; McLeod SM
Antimicrob Agents Chemother; 2024 May; 68(5):e0169823. PubMed ID: 38567976
[No Abstract] [Full Text] [Related]
3.
Karlowsky JA; Hackel MA; McLeod SM; Miller AA
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0078122. PubMed ID: 36005804
[TBL] [Abstract][Full Text] [Related]
4. Pathogen-Targeted Clinical Development to Address Unmet Medical Need: Design, Safety, and Efficacy of the ATTACK Trial.
Watkins RR; Du B; Isaacs R; Altarac D
Clin Infect Dis; 2023 May; 76(Suppl 2):S210-S214. PubMed ID: 37125468
[TBL] [Abstract][Full Text] [Related]
5. Sulbactam-durlobactam: A novel β-lactam-β-lactamase inhibitor combination targeting carbapenem-resistant Acinetobacter baumannii infections.
El-Ghali A; Kunz Coyne AJ; Caniff K; Bleick C; Rybak MJ
Pharmacotherapy; 2023 Jun; 43(6):502-513. PubMed ID: 37052117
[TBL] [Abstract][Full Text] [Related]
6. Sulbactam/Durlobactam: First Approval.
Keam SJ
Drugs; 2023 Sep; 83(13):1245-1252. PubMed ID: 37523122
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes for Patients With Monomicrobial vs Polymicrobial
McLeod SM; Miller AA; Rana K; Altarac D; Moussa SH; Shapiro AB
Open Forum Infect Dis; 2024 Apr; 11(4):ofae140. PubMed ID: 38595956
[TBL] [Abstract][Full Text] [Related]
8. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii.
Seifert H; Müller C; Stefanik D; Higgins PG; Miller A; Kresken M
J Antimicrob Chemother; 2020 Sep; 75(9):2616-2621. PubMed ID: 32516359
[TBL] [Abstract][Full Text] [Related]
10. Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant
Petropoulou D; Siopi M; Vourli S; Pournaras S
Front Cell Infect Microbiol; 2021; 11():814530. PubMed ID: 35127562
[TBL] [Abstract][Full Text] [Related]
11. Sulbactam-Durlobactam in the Treatment of Carbapenem-Resistant
August B; Matlob A; Kale-Pradhan PB
Ann Pharmacother; 2024 Jul; 58(7):735-741. PubMed ID: 37817550
[TBL] [Abstract][Full Text] [Related]
12. Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting
McLeod SM; O'Donnell JP; Narayanan N; Mills JP; Kaye KS
Future Microbiol; 2024 Mar; ():. PubMed ID: 38426849
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
Jean SS; Hsieh TC; Hsu CW; Lee WS; Bai KJ; Lam C
J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302
[TBL] [Abstract][Full Text] [Related]
14. Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of
Moussa SH; Shapiro AB; McLeod SM; Iyer R; Carter NM; Tsai Y-K; Siu LK; Miller AA
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0066523. PubMed ID: 37843305
[No Abstract] [Full Text] [Related]
15.
McLeod SM; Moussa SH; Hackel MA; Miller AA
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988095
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
[TBL] [Abstract][Full Text] [Related]
17. Sulbactam-durlobactam susceptibility test method development and quality control ranges for MIC and disk diffusion tests.
McLeod SM; Carter NM; Huband MD; Traczewski MM; Bradford PA; Miller AA
J Clin Microbiol; 2024 Jan; 62(1):e0122823. PubMed ID: 38095417
[TBL] [Abstract][Full Text] [Related]
18.
O'Donnell J; Tanudra A; Chen A; Newman J; McLeod SM; Tommasi R
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0080023. PubMed ID: 38092671
[TBL] [Abstract][Full Text] [Related]
19. Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia.
Yilmaz GR; Guven T; Guner R; Kocak Tufan Z; Izdes S; Tasyaran MA; Acikgoz ZC
J Infect Dev Ctries; 2015 May; 9(5):476-85. PubMed ID: 25989167
[TBL] [Abstract][Full Text] [Related]
20.
O'Donnell J; Tanudra A; Chen A; Miller AA; McLeod SM; Tommasi R
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0031223. PubMed ID: 38092676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
